Putting the Foxes in Charge of the Henhouse: The Dramatic Race to Develop an Artificial Pancreas
The true story of how artificial pancreas systems moved from an idea to a therapy, improving the lives of millions with type 1 diabetes.
ADA Takeaways: Day 2
At the ADA Scientific Sessions, scientists will present the latest T1D research, all with the goal of improving lives for the T1D community.
Powering research breakthroughs
We invest in the most promising research to turn ideas into life-changing therapies and lead the way to cures.
Top Type 1 Diabetes Advances of Fiscal Year 2023
Breakthrough T1D highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.
A Bittersweet Goodbye for Breakthrough T1D Champion Cynthia Rice
JDRF’s Chief Mission Strategy Officer will leave behind quite a legacy once she steps down from her role at Breakthrough T1D at the end of March 2023.
New Study Shows Kids 1+ Benefit from Artificial Pancreas Technology
A new paper published in the New England Journal of Medicine shows hybrid closed loop systems help children as young as 1 year old achieve better glycemic control.
Artificial pancreas systems: Sleeping without fear
Research shows Artificial Pancreas Systems can help improve diabetes-related outcomes and lighten the burden of T1D. Even during sleep.
SFC Fluidics, a Breakthrough T1D Partner, Receives Breakthrough Device Designation
SFC Fluidics, a Breakthrough T1D partner, received a breakthrough device designation for its interoperable insulin delivery pod. How is it different? Find out here.
Tandem Control-IQ Improves T1D Management in Children Ages 6 and Up
A clinical trial at four pediatric diabetes centers in the United States has found that a new artificial pancreas system—which automatically monitors and regulates blood-sugar levels—is safe and effective in children as young as age six with type 1 diabetes (T1D): Tandem’s t:slim X2™ insulin pump with Control-IQ™ technology. The algorithm in the Control-IQ technology […]
Tandem Control-IQ—Now Authorized For Children
Tandem Diabetes announced FDA clearance of an expanded pediatric indication for the Tandem t:slim X2™ insulin pump with Control-IQ™ technology in children ages six and older.
